what is Abecma (By AI)
Abecma (generic name: idecabtagene vicleucel) is a CAR T-cell therapy used to treat certain types of blood cancer, specifically:
Approved Use
-
Relapsed or refractory multiple myeloma in adult patients who have received at least four prior lines of therapy, including:
-
An immunomodulatory agent (e.g., lenalidomide),
-
A proteasome inhibitor (e.g., bortezomib),
-
An anti-CD38 monoclonal antibody (e.g., daratumumab).
-
How It Works
Abecma is a personalized gene therapy. It involves:
-
Collecting T cells from the patient's blood.
-
Genetically modifying them in a lab to express a chimeric antigen receptor (CAR) that targets BCMA (B-cell maturation antigen) — a protein highly expressed on multiple myeloma cells.
-
Reinfusing the modified T cells into the patient to seek out and destroy cancer cells.
Manufacturer
-
Co-developed by Bristol Myers Squibb and bluebird bio.
Approval
-
Approved by the FDA in March 2021, the first CAR T-cell therapy specifically for multiple myeloma.
Side Effects
-
Common: Fatigue, cytokine release syndrome (CRS), infections, low blood counts, neurotoxicity.
-
Serious side effects can be life-threatening, requiring hospitalization and intensive monitoring.
تعليقات
إرسال تعليق